cbdMD Inc (YCBD) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
cbdMD Inc stock (YCBD) is currently trading at $0.77. cbdMD Inc PE ratio is 1.45. cbdMD Inc PS ratio (Price-to-Sales) is 0.42. Analyst consensus price target for YCBD is $2.00. WallStSmart rates YCBD as Sell.
- YCBD PE ratio analysis and historical PE chart
- YCBD PS ratio (Price-to-Sales) history and trend
- YCBD intrinsic value — DCF, Graham Number, EPV models
- YCBD stock price prediction 2025 2026 2027 2028 2029 2030
- YCBD fair value vs current price
- YCBD insider transactions and insider buying
- Is YCBD undervalued or overvalued?
- cbdMD Inc financial analysis — revenue, earnings, cash flow
- YCBD Piotroski F-Score and Altman Z-Score
- YCBD analyst price target and Smart Rating
cbdMD Inc
📊 No data available
Try selecting a different time range
YCBD Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · cbdMD Inc (YCBD)
YCBD trades at a significant discount to its Graham intrinsic value of $3.47, offering a 78% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
cbdMD Inc (YCBD) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, price/book. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
cbdMD Inc (YCBD) Key Strengths (2)
Paying less than $1 for every $1 of annual revenue
Trading below book value, meaning the market prices it less than net assets
Supporting Valuation Data
cbdMD Inc (YCBD) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Revenue declining -11.00%, a shrinking business
Company is losing money with a negative profit margin
Very low institutional interest at 5.63%
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
cbdMD Inc (YCBD) Detailed Analysis Report
Overall Assessment
This company scores 29/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 2 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 0.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales, Price/Book. Valuation metrics including Price/Sales (0.42), Price/Book (0.79) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Growth concerns include Revenue Growth at -11.00%, which may limit upside. Profitability pressure is visible in Return on Equity at -33.10%, Operating Margin at -19.60%, Profit Margin at -7.96%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -33.10% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -11.00% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
YCBD Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
YCBD's Price-to-Sales ratio of 0.42x trades 38% below its historical average of 0.67x (60th percentile). The current valuation is 94% below its historical high of 6.48x set in May 2019, and 736% above its historical low of 0.05x in Mar 2023. Over the past 12 months, the PS ratio has expanded from ~0.1x, reflecting growing market expectations outpacing revenue growth.
Compare YCBD with Competitors
Top DRUG MANUFACTURERS - SPECIALTY & GENERIC stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for cbdMD Inc (YCBD) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
cbdMD Inc is in a turnaround phase, with management focused on restoring profitability. Revenue reached 19M with 11% decline year-over-year. The company is currently unprofitable, posting a -8.0% profit margin.
Key Findings
Revenue contracted 11% YoY. Worth determining whether this is cyclical or structural.
The company is unprofitable with a -8.0% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Volatility is elevated with a beta of 2.21, so expect amplified moves relative to the broader market.
Sector dynamics: monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive moves, and regulatory changes that could impact cbdMD Inc.
Bottom Line
cbdMD Inc is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(0 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 11:35:47 AM
About cbdMD Inc(YCBD)
NYSE MKT
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
cbdMD, Inc. produces and distributes various cannabidiol (CBD) products. The company is headquartered in Charlotte, North Carolina.